EMVision Medical Devices Ltd engages in the research, development, and commercialization of neurodiagnostic technology for stroke diagnosis and monito...
| EMV | Peers | Sector | |
|---|---|---|---|
Market Cap | 162.5 M | 29.828 M | 99.789 M |
Price % of 52 Week High | 80.9% | 43.5% | 60.4% |
Dividend Yield | 0.0% | 0.0% | 0.0% |
Shareholder Yield | -9.3% | -14.7% | -0.7% |
1 Year Price Total Return | -15.2% | -20.5% | -12.0% |
Beta (5 Year) | 1.27 | 0.72 | 0.64 |
No data available
| (presentment in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Jun-23 | Jun-24 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 6.97 | 11 | 8.06 | 3.32 | 1.74 |
| Operating Income | (3.96) | (2.26) | (5.92) | 0.16 | (1.67) |
| Net Profit | (3.87) | (2.73) | (6.19) | (0.06) | (1.79) |
| Diluted EPS | -0.050 | -0.034 | -0.074 | -0.00072 | -0.021 |
| EBITDA | (3.83) | (2.09) | (5.75) | 0.26 | (1.57) |
| Balance Sheet | |||||
| Cash & ST Invest. | 9.90 | 19 | 14 | 8.48 | 14 |
| Current Assets | 10 | 22 | 17 | 10 | 17 |
| Total Assets | 12 | 24 | 20 | 11 | 20 |
| Current Liabilities | 6.04 | 3.41 | 2.02 | 5.28 | 2.02 |
| Total Liabilities | 6.40 | 5.46 | 4.46 | 5.53 | 4.46 |
| Total Equity | 5.12 | 19 | 15 | 5.71 | 15 |
| Total Debt | 3.04 | 2.90 | 2.81 | 2.97 | 2.81 |
| Cash Flow Statement | |||||
| Cash Flow Operations | 0.83 | (5.99) | (9.50) | (0.66) | (2.42) |
| Cash From Investing | (0.19) | (0.30) | (0.29) | (0.02) | (0.02) |
| Cash From Financing | 2.45 | 15 | 15 | (0.06) | (0.06) |
| Free Cash Flow | 0.65 | (6.11) | (9.60) | (0.68) | (2.43) |